Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

Published:2015-11-06 Issue:1 Volume:6 Page:36-44
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Russo Mariangela,Misale Sandra,Wei Ge,Siravegna Giulia,Crisafulli Giovanni,Lazzari Luca,Corti Giorgio,Rospo Giuseppe,Novara Luca,Mussolin Benedetta,Bartolini Alice,Cam Nicholas,Patel Roopal,Yan Shunqi,Shoemaker Robert,Wild Robert,Di Nicolantonio Federica,Bianchi Andrea Sartore,Li Gang,Siena Salvatore,Bardelli Alberto

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 263 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors;npj Precision Oncology;2024-09-11

2. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

3. Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies;Journal of Medicinal Chemistry;2024-08-15

4. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents;British Journal of Cancer;2024-06-20

5. A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas;European Journal of Cancer;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP